Article
A Prospective Phase II Single-arm Study of Niraparib Plus Dostarlimab in Patients With Advanced Non-small-cell Lung Cancer and/or Malignant Pleural Mesothelioma, Positive for PD-L1 Expression and Germline or Somatic Mutations in the DNA Repair Genes: Rationale and Study Design.
Clinical lung cancer - 1 Jan 2021
Passiglia Francesco, Bironzo Paolo, Righi Luisella, Listì Angela, Arizio Francesca, Novello Silvia, Volante Marco, Scagliotti Giorgio Vittorio
Abstract excerpt
Treatment with poly ADP ribose polymerase (PARP)1/2 inhibitors represents a novel opportunity to selectively kill a subset of cancer cell types by exploiting their deficiencies in DNA repair, thus leading to synthetic lethality. Treatment of homologous recombination deficient (HRD)-tumors with PARP inhibitors generates significant levels of DNA damage, which has the potential to further increasing tumor...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.